DEK :: AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma : A Clinical Outcome Study Compared With Conventional Sinonasal Squamous Cell Carcinoma
- PMID: 39719672
- DOI: 10.1097/PAS.0000000000002335
DEK :: AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma : A Clinical Outcome Study Compared With Conventional Sinonasal Squamous Cell Carcinoma
Abstract
DEK :: AFF2 fusion nonkeratinizing squamous cell carcinoma (NKSCC) is an emerging entity in the sinonasal tract, temporal bone, and skull base. However, the clinical behavior of these tumors has not been well studied. Here, we report the largest cohort of DEK :: AFF2 carcinomas to determine if morphology, mitotic rate, and/or Ki-67 IHC are associated with patient outcomes, including a comparison with high-risk human papillomavirus (HPV)-associated and independent patients. We solicited cases of molecularly or AFF2 immunohistochemistry (IHC) proven DEK :: AFF2 SCC from surgical pathologists to collect patient demographic, clinical, and outcome data. Using representative H&E slides, we characterized the morphology and counted mitoses. Ki-67 immunohistochemistry was performed. We also compared the DEK :: AFF2 survival rates to those in a cohort of AFF2 IHC-negative HPV-associated and HPV-independent SCC. DEK :: AFF2 carcinomas most commonly arose in the nasal cavity (13/30, 43%), and the average number of recurrences was 1.8 (range: 0 to 10). At the last follow-up, most patients were disease free (19/30, 63%) or were alive with disease (9/30, 30%). There was an average mitotic rate of 2 per 2 mm 2 (range: 0 to 9) and Ki-67 proliferation rate of 26% (range: 3% to 60%). Local recurrence was common, but morphology, mitotic activity, and Ki-67 index were not associated with recurrence or survival. On Kaplan-Meier survival analysis, DEK :: AFF2 patients had lower disease-free survival but otherwise had similar outcomes to conventional SCC patients. Our multi-institutional study shows that local recurrence is common in DEK :: AFF2 fusion nonkeratinizing SCC patients, but patients have survival rates similar to conventional SCC. Despite showing a range of different features and proliferation rates, traditional grading by morphology, mitotic rate, and/or Ki-67 activity does not seem to be predictive of outcome.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Similar articles
-
DEK::AFF2-Associated Papillary Squamous Cell Carcinoma of the Sinonasal Tract: Clinicopathologic Characterization of 9 Cases.Head Neck Pathol. 2025 May 20;19(1):66. doi: 10.1007/s12105-025-01799-7. Head Neck Pathol. 2025. PMID: 40392381
-
DEK-AFF2 Carcinoma of the Sinonasal Region and Skull Base: Detailed Clinicopathologic Characterization of a Distinctive Entity.Am J Surg Pathol. 2021 Dec 1;45(12):1682-1693. doi: 10.1097/PAS.0000000000001741. Am J Surg Pathol. 2021. PMID: 34049316
-
DEK::AFF2 Fusion-Associated Squamous Cell Carcinoma: A Case Series with Literature Review on an Emerging and Challenging Entity.Head Neck Pathol. 2024 Sep 23;18(1):86. doi: 10.1007/s12105-024-01690-x. Head Neck Pathol. 2024. PMID: 39312022 Review.
-
DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology.Mod Pathol. 2021 Oct;34(10):1820-1830. doi: 10.1038/s41379-021-00846-2. Epub 2021 Jun 9. Mod Pathol. 2021. PMID: 34108636
-
DEK::AFF2 Squamous Cell Carcinomas of the Sinonasal Region and Temporal Bone Diagnosed After Recurrences: A Report of Two Patients.Int J Surg Pathol. 2025 Aug;33(5):1258-1266. doi: 10.1177/10668969241301061. Epub 2025 Jan 17. Int J Surg Pathol. 2025. PMID: 39819065 Review.
Cited by
-
Expanding the spectrum of AFF2 carcinoma: clinical, morphological, immunohistochemical, and molecular characteristics of five cases harboring alternate fusions.Virchows Arch. 2025 Jun 10. doi: 10.1007/s00428-025-04140-3. Online ahead of print. Virchows Arch. 2025. PMID: 40494991
-
DEK::AFF2-Associated Papillary Squamous Cell Carcinoma of the Sinonasal Tract: Clinicopathologic Characterization of 9 Cases.Head Neck Pathol. 2025 May 20;19(1):66. doi: 10.1007/s12105-025-01799-7. Head Neck Pathol. 2025. PMID: 40392381
-
Primary Laryngeal Squamous Cell Carcinoma with DEK::AFF2 Fusion: The First Case Report.Head Neck Pathol. 2025 Apr 29;19(1):51. doi: 10.1007/s12105-025-01793-z. Head Neck Pathol. 2025. PMID: 40299135 Free PMC article.
References
-
- Bishop JA, Loney EL, Thompson LDR. Nasal Cavity, Paranasal Sinuses, and Skull Base Tumours, 5th ed. International Agency for Research on Cancer; 2022.
-
- Yang W, Lee KW, Srivastava RM, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019;25:767–775.
-
- Todorovic E, Truong T, Eskander A, et al. Middle ear and temporal bone nonkeratinizing squamous cell carcinomas with DEK-AFF2 fusion: an emerging entity. Am J Surg Pathol. 2020;44:1244–1250.
-
- Lewis Jr JS, Chernock RD, Haynes W, et al. Low-grade papillary schneiderian carcinoma, a unique and deceptively bland malignant neoplasm: report of a case. Am J Surg Pathol. 2015;39:714–721.
-
- Zhai C, Wang H, Li S, et al. Clinicopathological analysis of low-grade papillary Schneiderian carcinoma: report of five new cases and review of the literature. Histopathology. 2021;79:370–380.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous